Asthma Conf 09: : Asthma Treatment And Safety

5 Questions | By Ahalaja | Updated: Mar 21, 2022 | Attempts: 139

1. Enter your name, including first name, last name plus credentials2. Password: pafp13. Click "start quiz" 4. Answer the five multiple choice questions to receive a test score and a link to your CME certificate. PAFP members, your reward point will be added to your member record after you complete the post-test. (Be sure to provide your name so that we assign your reward point!)

Questions and Answers

1.

According to the GAPP survey, who initiates discussion about asthma medication side effects, adult patients or physicians?
- A.
  
  Adult patients are most likely to initiate the conversation
- B.
  
  Physicians are most likely to initiate the conversation
- C.
  
  Adult patients and physicians both thought they initiated the conversation themselves
- D.
  
  This conversation frequently didn’t occur
2.

The risks of (Glucocorticosteroid, GCS) corticosteroids use decrease when the medications are inhaled, at a low dose with a newer drug with negative growth studies.
- A.
  
  True
- B.
  
  False
3.

Multiple oral corticosteroid bursts over years of time can produce a dose-dependent reduction in bone mineral accretion and (increased risk for osteopenia) in children with asthma. Inhaled corticosteroid use might do the same in boys progressing through puberty, but this risk is likely to be outweighed by the ability to reduce the amount of oral corticosteroids used in these children.
- A.
  
  True
- B.
  
  False
4.

Studies show cataracts and glaucoma risks only go up when at high doses of inhaled steroids. At low doses there is not much risk shown.
- A.
  
  True
- B.
  
  False
5.

What is the #1 risk to patients with asthma?
- A.
  
  Treated with oral corticosteroid
- B.
  
  Treated, stepped-down doses of inhaled corticosteroids
- C.
  
  Treated with greater than recommended doses of inhaled corticosteroid
- D.
  
  Untreated poorly controlled disease
- E.
  
  Treated with recommended doses of inhaled corticosteroid